1-12 of 12
Joel Morris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB_A21: NCI60 HTS384: The next phase of the NCI60 screen

Beverly A Teicher, Mark W Kunkel, Joel Morris, Ronald C Taylor, Thomas S Dexheimer, Nathan P Coussens, James H Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): LB_A21.
https://doi.org/10.1158/1535-7163.TARG-23-LB_A21
Published: 01 December 2023
View article titled, Abstract LB_A21: NCI60 HTS384: The next phase of the NCI60 screen
Journal Articles

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource

Joel Morris, Mark W. Kunkel, Stephen L. White, Donn G. Wishka, Omar D. Lopez, Lori Bowles, Penny Sellers Brady, Patricia Ramsey, Julie Grams, Tiffany Rohrer, Karen Martin, Thomas S. Dexheimer, Nathan P. Coussens, David Evans, Prabhakar Risbood, Dmitriy Sonkin, John D. Williams, Eric C. Polley, Jerry M. Collins, James H. Doroshow, Beverly A. Teicher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (11): 1270–1279.
https://doi.org/10.1158/1535-7163.MCT-23-0267
Published: 01 November 2023
View article titled, Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
Open the PDF for Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource in another window
Includes: Supplementary data
Journal Articles

F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd

Joel Morris, Donn G. Wishka, Omar D. Lopez, Vladimir Rudchenko, Guangfei Huang, Sierra N. Hoffman, Suzanne Borgel, Kyle Georgius, John Carter, Howard Stotler, Mark W. Kunkel, Jerry M. Collins, Melinda G. Hollingshead, Beverly A. Teicher
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (4): 625–631.
https://doi.org/10.1158/1535-7163.MCT-20-0738
Published: 01 April 2021
View article titled, F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd
Open the PDF for F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd in another window
Includes: Supplementary data
Journal Articles

Abstract B67: Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression

Beverly A. Teicher, Eric Polley, Mark Kunkel, David Evans, Thomas Silvers, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, Joel Morris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B67.
https://doi.org/10.1158/1535-7163.TARG-15-B67
Published: 01 December 2015
View article titled, Abstract B67: Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression
Journal Articles

Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression

Beverly A. Teicher, Eric Polley, Mark Kunkel, David Evans, Thomas Silvers, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, Joel Morris
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2452–2462.
https://doi.org/10.1158/1535-7163.MCT-15-0074
Published: 03 November 2015
View article titled, Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
Open the PDF for Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression in another window
Includes: Supplementary data
Journal Articles

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow, Yves Pommier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 433–443.
https://doi.org/10.1158/1535-7163.MCT-13-0803
Published: 09 February 2014
View article titled, Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Open the PDF for Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib in another window
Includes: Supplementary data
Journal Articles

Abstract A102: NCI-60 response profiles of >400 investigational oncology agents: A resource enabling drug and biomarker discovery.

Joel Morris, Mark Kunkel, Eric Polley, Susan Holbeck, Kazimierz Wrzeszczynski, Anne Monks, David Evans, Annamaria Rapisarda, Jerry Collins, Beverly A. Teicher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A102.
https://doi.org/10.1158/1535-7163.TARG-13-A102
Published: 01 November 2013
View article titled, Abstract A102: NCI-60 response profiles of >400 investigational oncology agents: A resource enabling drug and biomarker discovery.
Journal Articles

Abstract C106: Screening small cell lung cancer lines against approved oncology drugs and investigational agents elucidates patterns of sensitivity.

David M. Evans, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Thomas Silvers, Anne Monks, Gurmeet Kaur, Joel Morris, Beverly A. Teicher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C106.
https://doi.org/10.1158/1535-7163.TARG-13-C106
Published: 01 November 2013
View article titled, Abstract C106: Screening small cell lung cancer lines against approved oncology drugs and investigational agents elucidates patterns of sensitivity.
Journal Articles

Abstract A257: Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib.

Junko Murai, Shar-yin N. Huang, Amelie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow, Yves Pommier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A257.
https://doi.org/10.1158/1535-7163.TARG-13-A257
Published: 01 November 2013
View article titled, Abstract A257: Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib.
Journal Articles

Abstract CN05-01: PARP inhibitors: Trapping of PARP and rational for combinations.

Yves G. Pommier, Junko Murai, Joel Morris, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): CN05-01.
https://doi.org/10.1158/1535-7163.TARG-13-CN05-01
Published: 01 November 2013
View article titled, Abstract CN05-01: PARP inhibitors: Trapping of PARP and rational for combinations.
Journal Articles

Abstract C222: The identification of kinase targets in Ewing sarcoma cell lines using RNAi and high-throughput investigational agents screens.

Amy McCalla, Patrick Grohar, Scott Martin, Eugen Buehler, Suntae Kim, Natasha Caplen, Joel Morris, Mark Kunkel, David Evans, Anne Monks, Beverly Teicher, Lee Helman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C222.
https://doi.org/10.1158/1535-7163.TARG-13-C222
Published: 01 November 2013
View article titled, Abstract C222: The identification of kinase targets in Ewing sarcoma cell lines using RNAi and high-throughput investigational agents screens.
Journal Articles

Abstract C103: Sarcoma cell line sensitivity towards approved oncology drugs and investigational agents identifies distinct patterns of response which can be interrogated with associated gene expression.

Anne Monks, David Evans, Thomas Silvers, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, John Connelly, Annamaria Rapisarda, Mark Kunkel, Joel Morris, Kazimierz Wrzeszczynski, Eric Polley, Beverley Teicher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C103.
https://doi.org/10.1158/1535-7163.TARG-13-C103
Published: 01 November 2013
View article titled, Abstract C103: Sarcoma cell line sensitivity towards approved oncology drugs and investigational agents identifies distinct patterns of response which can be interrogated with associated gene expression.